The U.S. Food and Drug Administration on Tuesday authorized a second dose of Omicron-targeting COVID-19 vaccines for older adults as well as those with a weak immune system.
Pfizer Inc. and its German partner BioNTech SE said on Monday they have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization of their Omicron-adapted COVID-19 vaccine booster for children aged 6 months through 4 years.
Pfizer Inc. and its partner BioNTech said on Thursday the EU health regulator has recommended authorizing the use of their bivalent COVID-19 shot as a booster in children aged 5 through 11.
U.S. President Joe Biden will get his updated COVID-19 vaccine on Tuesday and urge more Americans to get the latest shot, White House spokesman Kevin Munoz said on Sunday.
Moderna Inc. said on Wednesday its COVID-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months.
Moderna Inc. (MRNA.O) has agreed to provide its new variant-adapted COVID-19 vaccine to the global scheme aiming to deliver shots to the world’s poorest people.
Canada on Friday authorized updated COVID-19 booster shots from Pfizer Inc. and its partner BioNTech SE that target the Omicron BA.4 and BA.5 subvariants, according to the government’s website.
Around two-thirds of adults in the United States do not plan to get updated COVID-19 booster shots soon, according to a survey conducted by the Kaiser Family Foundation (KFF), a health policy nonprofit organization.
Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.
The U.S. Centers for Disease Control and Prevention expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October.